Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for Conferences in all fields of Science, Engineering, Arts, and Humanities. The purpose of the Conferences is to bring together individuals with common interests to examine the emerging and most advanced aspects of their particular field.

The Symposium on Ovarian Cancer: State of the Art and Future Directions intends to bring together international experts interested in the development of novel diagnostic, prognostic and therapeutic tools for ovarian cancer. The meeting will function as a think tank where clinicians, translational and basic scientists, and parties from the biotechnology and pharmaceutical industry will get together to review recent advances in clinical research and translational science in ovarian cancer and define areas of future research opportunities and priorities.

Meeting will function as a think tank where clinicians, translational and basic scientists, and parties from the biotechnology and pharmaceutical industry will get together to review recent advances in clinical research and translational science in ovarian cancer and define areas of future research opportunities and priorities

Inhalt
Ovarian Cancer Detection and Pathogenesis.- Potential and Limitations in Early Diagnosis of Ovarian Cancer.- SMRP and HE4 as Biomarkers for Ovarian Carcinoma When Used Alone and in Combination with CA125 and/or Each Other.- Classification of Ovarian Cancer: A Genomic Analysis.- Epigenetic Markers of Ovarian Cancer.- Role of Genetic Polymorphisms in Ovarian Cancer Susceptibility: Development of an International Ovarian Cancer Association Consortium.- MicroRNA in Human Cancer: One Step Forward in Diagnosis and Treatment.- Ovarian Carcinogenesis: An Alternative Hypothesis.- BRCA1-Induced Ovarian Oncogenesis.- Role of p53 and Rb in Ovarian Cancer.- Ovulatory Factor in Ovarian Carcinogenesis.- Ovarian Cancer Therapeutics.- Gynecologic Oncology Group (GOG-USA) Trials in Ovarian Cancer.- Intraperitoneal Chemotherapy for Ovarian Cancer.- Ovarian Cancer: Can We Reverse Drug Resistance?.- Syngeneic Mouse Model of Epithelial Ovarian Cancer: Effects of Nanoparticulate Paclitaxel, Nanotax®.- Individualized Molecular Medicine: Linking Functional Proteomics to Select Therapeutics Targeting the PI3K Pathway for Specific Patients.- Defective Apoptosis Underlies Chemoresistance in Ovarian Cancer.- Nanoparticle Delivery of Suicide DNA for Epithelial Ovarian Cancer Therapy.- Biological Therapy with Oncolytic Herpesvirus.- Cancer Immunotherapy: Perspectives and Prospects.- Regulatory T Cells: A New Frontier in Cancer Immunotherapy.- Inhibitory B7 Family Members in Human Ovarian Carcinoma.- Role of Vascular Leukocytes in Ovarian Cancer Neovascularization.- Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a New Target Molecule for Cancer Therapy.